Arthrosi Therapeutics is a clinical-stage biotech company focusing on the development of gout and chronic kidney diseases. Its proprietary drug candidate, AR882, demonstrated unprecedent sustained urate lowering in gout patients with the potential of providing other therapeutic benefits in clinical development.